Skip to content
The Policy VaultThe Policy Vault

Firazyr — Blue Cross Blue Shield of New Mexico

hereditary angioedema (HAE)

Initial criteria

  • ONE of the following: (A) The requested agent is eligible for continuation of therapy AND the prescriber states the patient has been treated with the requested agent (starting on samples is not approvable) AND is at risk if therapy is changed; OR (B) initial evaluation criteria continue as defined beyond this section.